REDWOOD CITY, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX) today reported that the company's Oncotype DX(TM)
breast cancer assay, used to predict the likelihood of disease recurrence
and likelihood of chemotherapy benefit for node-negative, estrogen
receptor-positive breast cancer patients, has been included in updated
guidelines on the use of breast cancer tumor markers by the American
Society of Clinical Oncology (ASCO). The inclusion of Oncotype DX in ASCO's
updated clinical practice guidelines represents a significant step forward
for the role of molecular diagnostics in breast cancer treatment planning.
These guidelines were published online today in the Journal of Clinical
Oncology and will appear in the journal's November 20th print edition.

"We are delighted that ASCO, the leading professional organization
representing physicians who treat people with cancer, has recommended the
use of Oncotype DX and differentiated it as an optimal tool for breast
cancer treatment selection," said Steve Shak, M.D., chief medical officer
at Genomic Health. "Physicians have used Oncotype DX for treatment planning
in more than 33,000 patients. We believe this, in addition to the new ASCO
Guidelines and extensive reimbursement, indicates that the use of Oncotype
DX is becoming standard practice for physicians and women making individual
breast cancer treatment decisions."

The inclusion of Oncotype DX in ASCO's updated clinical practice
guidelines is based on multiple independent clinical studies involving more
than 2,600 breast cancer patients, including a large validation study
published in The New England Journal of Medicine and a chemotherapy benefit
study published in the Journal of Clinical Oncology. ASCO Guidelines serve
as a guide for doctors and outline appropriate methods of treatment and
care.

"It's important to note that ASCO's new guidelines only include markers
with a proven clinical decision-making impact that are based on a high
level of clinical validation," said Gabriel N. Hortobagyi MD, FACP,
Professor and Chairman, Department of Breast Medical Oncology, The
University of Texas M.D. Anderson Cancer Center. "While exciting research
and multiple prognostic tools are available today, Oncotype DX is the only
genomic test that has sufficient clinical evidence to support its use in
clinical practice."

About Oncotype DX

Oncotype DX is the first diagnostic multi-gene expression test
commercially available that has clinical evidence validating its ability to
predict the likelihood of breast cancer recurrence, the likelihood of
breast cancer survival and the likelihood of chemotherapy benefit. Oncotype
DX has been extensively evaluated in multiple independent studies involving
more than 2,600 breast cancer patients, including a large validation study
published in The New England Journal of Medicine and a chemotherapy benefit
study published in the Journal of Clinical Oncology. To date, over 6,000
physicians have ordered a cumulative total of more than 33,000 tests and
approximately 125 million lives are now covered by reimbursement contracts
and agreements. For more information about Oncotype DX, please visit
http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused
on the development and commercialization of genomic-based clinical
laboratory services for cancer that allow physicians and patients to make
individualized treatment decisions. In 2004, Genomic Health launched its
first test service, Oncotype DX(TM), which has been shown to predict the
likelihood of breast cancer recurrence and the likelihood of chemotherapy
benefit in a large portion of early-stage breast cancer patients. The
company was founded in 2000 and is located in Redwood City, California. For
more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including
statements relating to the Company's beliefs about the advancement of the
role of molecular diagnostics in breast cancer treatment, the belief that
the use of Oncotype DX is becoming standard practice in the treatment of
women with certain types of breast cancer, and the factors driving the use
of Oncotype DX in treatment decisions. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially. These risks and uncertainties include, but are not
limited to: the applicability of clinical results to actual outcomes; the
ability of our test to continue to impact treatment decisions; our ability
to increase usage of our tests; the risk that we may not obtain or maintain
sufficient levels of reimbursement for our existing tests and any future
tests we may develop; the risks and uncertainties associated with the
regulation of our test by FDA; our ability to obtain capital when needed;
our history of operating losses; the results of clinical studies and the
other risks set forth in our filings with the Securities and Exchange
Commission, including the risks set forth in our Quarterly Report on Form
10-Q for the six months ended June 30, 2007. These forward- looking
statements speak only as of the date hereof. Genomic Health disclaims any
obligation to update these forward-looking statements. NOTE: Genomic
Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score
are trademarks or registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective owners.

(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...

(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...

(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...

(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...

(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...

(Date:10/4/2017)... , Oct. 4, 2017 According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...